*Therapeutic Approach to NAFLD-NASH DOI: http://dx.doi.org/10.5772/intechopen.107487*

fatty acid oxidation and lowers steatosis and hyperlipidemia in animal models, whereas THR-a is important in cardiac function. These agonists, e.g., Resmetirom, have been employed in ongoing studies and have demonstrated a favorable impact on NAFLD [42].
